LEM reports consultancy with Boston Scientific
Methods This retrospective, database study used Optums de-identified Clinformatics Data Mart Database to identify glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment-nave adult patients with type 2 diabetes (T2D) initiating semaglutide QW, dulaglutide, liraglutide, or exenatide QW between January 1, 2018 and April 30, 2019
Activation of adenosine A 2A receptor reduces osteoclast formation via PKA- and ERK1/2-mediated suppression of NFB nuclear translocation
Treatment decisions should be discussed with your provider
GLP-1 receptor agonists for NAFLD treatment in patients with and without type 2 diabetes: an updated meta-analysis
If you already have or are at risk for type 2 diabetes, Ozempic may be the most practical starting point